Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Weavr Health Corp

Request full access

Developed easy-to-use, reliable blood collection devices to ensure anyone, anywhere can access the best health and wellness care

Cambridge, United StatesFounded 2005Health Tech & Medtech

About Weavr Health Corp

Weavr Health Corp., initially incorporated as Boston Microfluidics, Inc. in 2005, operated as a medical device developer focused on democratizing diagnostics through next-generation blood collection technology. The company's core mission was to create user-friendly, reliable devices for at-home blood collection, making testing more accessible and affordable. Weavr Health was acquired by Renegade.bio on March 23, 2023.

The company developed a portfolio of products designed to enable any adult user to collect high-quality, clinical-grade blood samples without the need for a phlebotomist or specialized laboratory equipment. Its flagship product, the Velvet™ blood collection device, was engineered to consistently collect a specific volume of whole blood and separate the sample into plasma and red blood cells. This process allows for more complex analysis and ensures sample stability at room temperature for an extended period, which simplifies logistics for lab transport. Another product, the Silk™ COVID-19 Rapid Antibody Test, was developed to provide rapid, qualitative detection of COVID-19 antibodies. The business model centered on supplying these devices to diagnostic laboratories, healthcare providers, and direct-to-consumer health companies. A significant partnership was established with Labcorp, which utilized the Velvet™ device for its Labcorp OnDemand at-home diabetes risk test, measuring HbA1c from a small blood sample. The collaboration involved an equity investment from Labcorp and resulted in the test being available nationwide after receiving approval from the New York State Clinical Laboratory Evaluation Program.

Before its acquisition, Weavr Health had raised a total of $24.2M in funding through multiple rounds, including investments from Anzu Partners and Labcorp Venture Fund. In January 2023, Nightingale Health acquired a worldwide license and rights to the Velvet™ device, allowing them to manufacture and use it in their preventative health services, having previously been a distributor. This move was strategic for Nightingale to integrate the self-collection technology more tightly into its global service delivery.

Source: Dealroom company data

Weavr Health Corp in the Cambridge ecosystem

Live from Dealroom

The Weavr Health Corp office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Anzu Partners
  • LabCorp

Series B and later1 investor entered at this stage

  • Nightingale Health
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Weavr Health Corp on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Weavr Health Corp on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.